Access to innovative HIV treatment 

Ten years after the signing of ground-breaking licensing agreements between ViiV Healthcare and the Medicines Patent Pool (MPP), as well as ViiV’s direct agreements with Aurobindo Pharma, more than 1 billion packs of generic dolutegravir (DTG) based medicines have reached 24 million people living with HIV in 128 low- and middle-income countries (LMICs), transforming the HIV landscape in those areas of the world. This means that as of 2023, over 90% of people on antiretroviral treatment in these countries are estimated to be on DTG-based regimens.

Thanks to this decade-long partnership, WHO-recommended treatment can be developed, produced, and when approved, supplied by 15 generic manufacturers to all low-income, least developed, lower-middle-income and sub-Saharan African countries, as well as some upper middle-income countries, addressing the needs of regions with the highest HIV burdens.

Charles Gore, Executive Director, Medicines Patent Pool said, “As we reflect on a decade of collaboration with ViiV Healthcare, we are proud to see that public health-oriented voluntary licensing has had tangible impact in the lives of the people we serve, enabling access to affordable versions of innovative HIV treatments in LMICs.”